Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Note=Localizes to chromatoid body (CB) and pi-body (also called intermitochondrial cementin), 2 cytoplasmic ribonucleoprotein granules involved in RNA processing for spermatogenesis. |
Domain |
PF12872 OST-HTH/LOTUS domain PF00567 Tudor domain |
Function |
Required during spermiogenesis to participate in the repression transposable elements and prevent their mobilization, which is essential for the germline integrity. Probably acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Required for chromatoid body (CB) assembly (By similarity). |
Biological Process |
GO:0000578 embryonic axis specification GO:0003002 regionalization GO:0006304 DNA modification GO:0006305 DNA alkylation GO:0006306 DNA methylation GO:0007028 cytoplasm organization GO:0007281 germ cell development GO:0007283 spermatogenesis GO:0007286 spermatid development GO:0007292 female gamete generation GO:0007308 oocyte construction GO:0007309 oocyte axis specification GO:0007314 oocyte anterior/posterior axis specification GO:0007315 pole plasm assembly GO:0007350 blastoderm segmentation GO:0007351 tripartite regional subdivision GO:0007389 pattern specification process GO:0008358 maternal determination of anterior/posterior axis, embryo GO:0008595 anterior/posterior axis specification, embryo GO:0009798 axis specification GO:0009880 embryonic pattern specification GO:0009948 anterior/posterior axis specification GO:0009952 anterior/posterior pattern specification GO:0009994 oocyte differentiation GO:0021700 developmental maturation GO:0022412 cellular process involved in reproduction in multicellular organism GO:0030719 P granule organization GO:0032259 methylation GO:0035282 segmentation GO:0043046 DNA methylation involved in gamete generation GO:0043414 macromolecule methylation GO:0044728 DNA methylation or demethylation GO:0048232 male gamete generation GO:0048469 cell maturation GO:0048477 oogenesis GO:0048515 spermatid differentiation GO:0048599 oocyte development GO:0071826 ribonucleoprotein complex subunit organization |
Molecular Function | - |
Cellular Component |
GO:0033391 chromatoid body GO:0035770 ribonucleoprotein granule GO:0036464 cytoplasmic ribonucleoprotein granule GO:0043186 P granule GO:0045495 pole plasm GO:0060293 germ plasm GO:0071546 pi-body |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between TDRD5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of TDRD5 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of TDRD5 in various data sets.
|
Points in the above scatter plot represent the mutation difference of TDRD5 in various data sets.
|
Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TDRD5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TDRD5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TDRD5. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TDRD5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of TDRD5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | TDRD5 |
Name | tudor domain containing 5 |
Aliases | FLJ34823; TUDOR3; Tudor domain-containing protein 5 |
Chromosomal Location | 1q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between TDRD5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |